TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22385032

Group type: EXPERIMENTAL
Intervention: Over the counter soft-solid antiperspirant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prescription aluminum chloride (6.5%) antiperspirant
Number of subjects: 0
Study: 20491723

Group type: EXPERIMENTAL
Intervention: Motivation Enhancement Treatment (MET)
Number of subjects: 1726

Group type: COMPARATOR
Intervention: Cognitive Behavioral Treatment (CBT)
Number of subjects: 1726
Study: 18946896

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 337

Group type: COMPARATOR
Intervention: Ioversol
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Iodixanol (diabetic subset)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Ioversol (diabetic subset)
Number of subjects: 337
Study: 16351808

Group type: EXPERIMENTAL
Intervention: CF/5‐FU + Taxol
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Taxol + OXA
Number of subjects: 180

Group type: COMPARATOR
Intervention: CF/5‐FU + DDP (control)
Number of subjects: 180
Study: 12430111

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375%
Number of subjects: 51

Group type: COMPARATOR
Intervention: Lidocaine 0.5%
Number of subjects: 51
Study: 10553503

Group type: EXPERIMENTAL
Intervention: DQB1*02‐DQA1*0501/DQB1*0302‐DQA1*0301 heterozygotes
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Simultaneous presence of both DRB1*03 and DQB1*0302
Number of subjects: 420

Group type: COMPARATOR
Intervention: DQB1*0302 among DRB1*04 patients
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: DRB1*03 among DQA1*0501 patients
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: DRB1*03 among DQB1*02 patients
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: DRB1*03‐DQA1*0501‐DQB1*02 haplotype
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: DRB1*04‐DQA1*0301‐DQB1*0302 haplotype
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: DRB1*0401
Number of subjects: 420
Study: 8691924

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Second BCG
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: BCG plus killed M leprae
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 1721129

Group type: EXPERIMENTAL
Intervention: Transcutaneous cardiac pacing (TCP)
Number of subjects: 51
Study: 7036282

Group type: EXPERIMENTAL
Intervention: Immunotherapy with levamisole
Number of subjects: 50

Group type: COMPARATOR
Intervention: No additional therapy (Control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (with and without levamisole)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 50
Study: 31852125

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extracts (GBEs) plus Shenmayizhi decoction (SMYZD) granule
Number of subjects: 196

Group type: COMPARATOR
Intervention: Ginkgo biloba extracts (GBEs) plus Shenmayizhi mimetic granule
Number of subjects: 196
Study: 29037649

Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique (MET)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Active Release Technique (ART)
Number of subjects: 64
Study: 26266414

Group type: EXPERIMENTAL
Intervention: Lactobacillus brevis (CD2)-containing lozenges, 4 tablets/day for 14 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24866253

Group type: EXPERIMENTAL
Intervention: Brief Narrative Exposure Therapy (brief NET), 3 sessions, conducted individually, in Arabic
Number of subjects: 63

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 63
Study: 21617197

Group type: EXPERIMENTAL
Intervention: Standard-dose cyclosporine (Stand-CsA)
Number of subjects: 1645

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine (Low-CsA)
Number of subjects: 1645

Group type: EXPERIMENTAL
Intervention: Low-dose sirolimus (Low-SRL)
Number of subjects: 1645

Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus (Low-Tac)
Number of subjects: 1645

Group type: EXPERIMENTAL
Intervention: Standard-dose cyclosporine (Stand-CsA) and Low-dose cyclosporine (Low-CsA)
Number of subjects: 1645

Group type: COMPARATOR
Intervention: All treatment arms
Number of subjects: 1645
Study: 19020496

Group type: EXPERIMENTAL
Intervention: Erythromycin (as a prototypical irreversible inhibitor of CYP3A)
Number of subjects: 30
Study: 17164159

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 37
Study: 16027511

Group type: EXPERIMENTAL
Intervention: P6 acupressure
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo acupressure
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 14510339

Group type: EXPERIMENTAL
Intervention: LDH-C4 activity in male partners of infertile couples
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: LDH-C4 activity in oligozoospermic samples
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: LDH-C4 activity and percentage sperm motility
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: LDH-C4 activity and Sperm Mitochondrial Activity Index (SMAI)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: LDH-C4 activity in azoospermic samples
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: LDH-C4 activity in vasectomised males
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: LDH-C4 activity in immature germ cells
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: LDH-C4 as a germinal epithelial marker
Number of subjects: 121
Study: 9718102

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Twelve-Step Facilitation (TSF)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Clinical replication costs for MET
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Clinical replication costs for TSF
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Clinical replication costs for CBT
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cost savings for MET compared to TSF
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cost savings for MET compared to CBT
Number of subjects: 3
Study: 7906428

Group type: EXPERIMENTAL
Intervention: Corticosteroid plus sulphasalazine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo plus sulphasalazine
Number of subjects: 11
Study: 3533371

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Aminophylline and Salbutamol (combined)
Number of subjects: 8
Study: 29385034

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 140

Group type: COMPARATOR
Intervention: Low-carb diet
Number of subjects: 140
Study: 26604069

Group type: EXPERIMENTAL
Intervention: Automated time‐lapse embryo assessment combined with morphologic assessment
Number of subjects: 319

Group type: COMPARATOR
Intervention: Morphologic assessment only (control group)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Test group patients receiving at least one TL‐high embryo
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Patients receiving only TL‐low embryos
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: TL‐high embryos
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: TL‐low embryos
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Morphologically good embryos (TL‐high)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Morphologically good embryos (TL‐low)
Number of subjects: 319
Study: 23350961

Group type: EXPERIMENTAL
Intervention: School-based intervention designed to enhance motivations to breastfeed delivered in two 35-min classroom sessions.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 42
Study: 23451440

Group type: EXPERIMENTAL
Intervention: Preoperative quadriceps exercise group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 60
Study: 20578855

Group type: EXPERIMENTAL
Intervention: Hawley retainers
Number of subjects: 40

Group type: COMPARATOR
Intervention: Perfector/Hawley retainers
Number of subjects: 40
Study: 17870625

Group type: EXPERIMENTAL
Intervention: Thoracic epidural bupivacaine and morphine
Number of subjects: 107

Group type: COMPARATOR
Intervention: Intercostal nerve cryoanalgesia
Number of subjects: 107
Study: 18987085

Group type: EXPERIMENTAL
Intervention: Eight-week, 16-hour training in self-management tools based on Easwaran's program
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 61
Study: 15356075

Group type: EXPERIMENTAL
Intervention: Intranasal atrial natriuretic peptide (ANP) 1 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11323729

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (maximum of 300 mg per day)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 128
Study: 9069306

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (CT) plus radiation therapy (RT)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 182
Study: 8450399

Group type: EXPERIMENTAL
Intervention: Pharmacological dose of recombinant human growth hormone (5.0 mg, every other day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Physiological dose of recombinant human growth hormone (2.5 mg, every other day)
Number of subjects: 10
Study: 3528672

Group type: EXPERIMENTAL
Intervention: G 115 (100 mg twice a day for 12 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31834937

Group type: EXPERIMENTAL
Intervention: Sunscreen containing avobenzone (2‐3%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sunscreen containing oxybenzone (0‐6%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sunscreen containing octocrylene (2.35‐10%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sunscreen containing ecamsule (2%)
Number of subjects: 0
Study: 29754029

Group type: EXPERIMENTAL
Intervention: MJ users
Number of subjects: 64

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 64
Study: 25708488

Group type: EXPERIMENTAL
Intervention: Fluconazole (6 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27129005

Group type: EXPERIMENTAL
Intervention: Omeprazole (60 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir (30 mg)
Number of subjects: 0
Study: 21901480

Group type: EXPERIMENTAL
Intervention: 300 mg/day isoflavones (aglycone equivalents)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study: 20184052

Group type: EXPERIMENTAL
Intervention: Pre-operative radiochemotherapy (PRE)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Postoperative radiochemotherapy (POST)
Number of subjects: 51
Study: 17497593

Group type: EXPERIMENTAL
Intervention: BCAA drink containing 2 g of BCAA and 0.5 g of Arg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isocaloric placebo drink
Number of subjects: 8
Study: 15023882

Group type: EXPERIMENTAL
Intervention: 10 mg of atorvastatin
Number of subjects: 45

Group type: COMPARATOR
Intervention: 40 mg of pravastatin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clopidogrel (375 mg loading dose, followed by 75 mg/d for at least 3 months)
Number of subjects: 45
Study: 11135381

Group type: EXPERIMENTAL
Intervention: Methoxamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study: 10399517

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine scalp circuit infiltration
Number of subjects: 26

Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 26
Study: 7771954

Group type: EXPERIMENTAL
Intervention: Lovastatin (L) 20 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pravastatin (P) 10 mg/day
Number of subjects: 48
Study: 3402855

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine (Marcaine, Sensorcaine) instillation into the wound prior to closure
Number of subjects: 0
Study: 28512859

Group type: EXPERIMENTAL
Intervention: Mindful-reappraisal intervention
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Reappraisal-only intervention
Number of subjects: 106

Group type: COMPARATOR
Intervention: Active control activity
Number of subjects: 106
Study: 27630213

Group type: EXPERIMENTAL
Intervention: Understanding of the purpose of the study
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Understanding of the procedures of the study
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Understanding of minimal risks associated with answering sensitive questions online
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Understanding that psychological treatment was not offered
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Incorrect indication of participation replacing current psychological treatment
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: Incorrect indication of no associated risks with participation
Number of subjects: 1179
Study: 26351776

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 supplementation that raised 25(OH)D levels to ≥32 ng/mL
Number of subjects: 35

Group type: COMPARATOR
Intervention: Continued low 25(OH)D levels (did not receive vitamin D3 supplementation)
Number of subjects: 35
Study: 23512062

Group type: EXPERIMENTAL
Intervention: Eritoran (105 mg total over 6 days)
Number of subjects: 1961

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1961
Study: 21369538

Group type: EXPERIMENTAL
Intervention: Active distraction (electronic gaming system)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Passive distraction (television)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No distraction
Number of subjects: 100
Study: 18350850

Group type: EXPERIMENTAL
Intervention: Whitening toothpaste containing Perlite (White System)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silica toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whitening toothpaste A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whitening toothpaste B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17206893

Group type: EXPERIMENTAL
Intervention: Tramadol drip (Group B)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Classical IV antispasmodic perfusion with sham drip (Group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sham perfusion and drip (Group C)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Sham perfusion and tramadol drip (Group D)
Number of subjects: 300
Study: 11807679

Group type: EXPERIMENTAL
Intervention: Voriconazole 6 mg/kg b.i.d. for 2 doses, then 3 mg/kg b.i.d. for 6-27 days, followed by 200 mg b.i.d. orally for up to 24 weeks
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Voriconazole in patients with pulmonary or tracheobronchial IA (n=84)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Voriconazole in patients with cerebral IA (n=19)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Voriconazole in patients with hematologic disorders (n=67)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Voriconazole in allogeneic stem cell transplant recipients (n=23)
Number of subjects: 116
Study: 10351588

Group type: EXPERIMENTAL
Intervention: Social work preadmission program including psychosocial evaluation, discharge planning, nursing and physiotherapy evaluations, and follow-up during hospitalization.
Number of subjects: 201

Group type: COMPARATOR
Intervention: Usual social work intervention after hospitalization (comparison group).
Number of subjects: 201
Study: 8749780

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Low or standard dose chemotherapy
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: S-phase fraction (SPF) analysis
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Different treatment regimens
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: SPF
Number of subjects: 1572
Study: 2293142

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg plus paracetamol 1 g 3 times daily
Number of subjects: 158

Group type: COMPARATOR
Intervention: Paracetamol 1 g 3 times daily
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Codeine 180 mg plus paracetamol 3 g
Number of subjects: 158
Study: 7016473

Group type: EXPERIMENTAL
Intervention: Teflon cannulas
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Polytetrafluorethylene (PTFE) cannulas
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Polyethylene (PE) cannulas
Number of subjects: 6
Study: 31462113

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vegetarian diet (VD)
Number of subjects: 0
Study: 30630183

Group type: EXPERIMENTAL
Intervention: Topical Lactococcus lactis emulsion applied twice daily for 30 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical Lactococcus lactis emulsion applied once daily for 4 days on reconstructed human epidermis
Number of subjects: 20
Study: 28369618

Group type: EXPERIMENTAL
Intervention: Safety norm audio
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control audio
Number of subjects: 120
Study: 26358536

Group type: EXPERIMENTAL
Intervention: Parent-based therapy for pediatric obesity (PBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parent and child family-based treatment (FBT)
Number of subjects: 0
Study: 24145933

Group type: EXPERIMENTAL
Intervention: Familial hypertension group (178 patients)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Normal control group (150 healthy adults)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Hypertension group (104 patients with no family history)
Number of subjects: 432
Study: 22283900

Group type: EXPERIMENTAL
Intervention: HIV-positive individuals
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: HIV-negative individuals
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: CD4 count < 50 cells/μl
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART) initiation
Number of subjects: 1195
Study: 19966363

Group type: EXPERIMENTAL
Intervention: Tulip-bud deployment method using Amplatzer Septal Occluder (ASO)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional method for ASD closure
Number of subjects: 27
Study: 17727392

Group type: COMPARATOR
Intervention: GLP-1
Number of subjects: 32

Group type: COMPARATOR
Intervention: Yohimbine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: GLP-1 and Yohimbine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15210457

Group type: EXPERIMENTAL
Intervention: Narrowband UV-B (NB-UV-B) phototherapy, 3 times a week for either 60 treatments or 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study: 11489463

Group type: EXPERIMENTAL
Intervention: (S)-MDE
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: (R)-MDE
Number of subjects: 5
Study: 9471481

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg each morning for 28 days, azithromycin 500 mg/day for 5 days, metronidazole 3 x 500 mg/day for 5 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Omeprazole 20 mg/day for 28 days, azithromycin 500 mg/day for 5 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 50
Study: 8016577

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg bid)
Number of subjects: 30
Study: 2455187

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dihydrochlorothiazide (THI)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination of Prazosin and Dihydrochlorothiazide
Number of subjects: 23
Study: 31146148

Group type: EXPERIMENTAL
Intervention: Let's Move It (LMI) intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 34
Study: 28764474

Group type: EXPERIMENTAL
Intervention: Time-reversal permutation with frame lengths of 4-32 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomization permutation with frame lengths of 1/8 to 2048 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time-reversal permutation with frame lengths exceeding about 100 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short frame lengths containing only a few speech samples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time-reversal permutation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomization permutation
Number of subjects: 0
Study: 24969222

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 3533

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 3533

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES) in DM subset
Number of subjects: 3533

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 3533

Group type: EXPERIMENTAL
Intervention: Routine angiographic follow-up
Number of subjects: 3533
Study: 23721208

Group type: EXPERIMENTAL
Intervention: Magnetic endoscopic imaging (MEI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard arm (using fluoroscopy on demand)
Number of subjects: 200
Study: 21742090

Group type: EXPERIMENTAL
Intervention: ω-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 1516

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1516
Study: 19774117

Group type: EXPERIMENTAL
Intervention: MA‐ES 625 mg/5 mL with a high-calorie, high-fat meal
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: MAOS 800 mg/20 mL
Number of subjects: 104

Group type: COMPARATOR
Intervention: Fasting MA‐ES
Number of subjects: 104

Group type: COMPARATOR
Intervention: Fasting MAOS
Number of subjects: 104

Group type: COMPARATOR
Intervention: Fed MA‐ES and MAOS
Number of subjects: 104
Study: 16397161

Group type: EXPERIMENTAL
Intervention: Focus groups and semistructured interviews with girls (N = 100) and boys (N = 77)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Development of TAAG interventions
Number of subjects: 177
Study: 15570274

Group type: EXPERIMENTAL
Intervention: Endovenous radiofrequency obliteration (RFO)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Ligation and vein stripping (S and L)
Number of subjects: 45